ADVAXIS INC(NASDAQ:ADXS) stock News

ADXS Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

a year ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

a year ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

a year ago - By: Ayala Pharmaceuticals - Mentions: IMNM

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

2 years ago - By: Ayala Pharmaceuticals - Mentions: IMNM

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

2 years ago - By: Immunome, Inc. - Mentions: IMNM

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

2 years ago - By: Ayala Pharmaceuticals - Mentions: IMNM

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors

2 years ago - By: Ayala Pharmaceuticals

Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

2 years ago - By: BusinessInsider - Mentions: KNOP CHPT ELEV HEI

Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023

2 years ago - By: Benzinga - Mentions: KNOP PCTY COIN HGBL ...

Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update

2 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee

3 years ago - By: Ayala Pharmaceuticals

Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

3 years ago - By: Advaxis, Inc.

Advaxis and Ayala Pharmaceuticals Complete Merger

3 years ago - By: Advaxis, Inc.

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

3 years ago - By: Benzinga - Mentions: AYLA

Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ

3 years ago - By: Advaxis, Inc.

Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

3 years ago - By: Advaxis, Inc.

Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update

3 years ago - By: Advaxis, Inc.

Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update

3 years ago - By: Advaxis, Inc.

ADVAXIS INC (ADXS) Stock News

ADXS Latest News, Press Relases and Analysis

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023

Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023

Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement

Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement

Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors

Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors

Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023

Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update

Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee

Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

Advaxis and Ayala Pharmaceuticals Complete Merger

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ

Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update

Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update

Advaxis, Inc. Announces 1-for-80 Reverse Stock Split